Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label pazopanib study in advanced hormone-resistant endometrial cancer
NL-OMON39290Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in endometrial cancer (EC) and Corpus Uteri Carcinoma, sponsored by Amsterdam University Medical Center. Primary endpoint: Percentage of patients free of progression at 3 months. Started Jan 2012; status: active, not recruiting.
02
Drugs
pazopanib
03
Conditions
endometrial cancer (EC)Corpus Uteri Carcinoma
Beyond the preview
Go deeper on NL-OMON39290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39290.